← All stocks

Aprea Therapeutics, Inc.

APRE Net buying
CIK 0001781983 #5292 in the set updated 21 Sep 2026
Bought (12 mo)
$60.91K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$60.91K
+$60.91K against sales at will

By person

10 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Gilad Oren
President/CEO
$25.01K (1)
+$25.01K
393,895
$350.57K
+18.8%
Duey Marc
Director
$25.00K (1)
+$25.00K
259,290
$230.77K
+23.5%
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
$10.90K (2)
+$10.90K
43,528
$38.74K
+130.7%
Seizinger Bernd R.
Director
48,910
$43.53K
+40.8%
HENNEMAN JOHN B III
Director
13,364
$11.89K
+45.5%
Pamukcu Rifat
Director
8,581
$7.64K
+95.0%
Peters Richard
Director
6,254
$5.57K
+201.5%
Grissinger Michael
Director
6,024
$5.36K
+226.7%
BIZZARI JEAN-PIERRE
Director
4,180
$3.72K
Gruia Gabriela
Director
4,180
$3.72K

No percentages here. This company's share count has moved by a factor of 2.3 over the window, from 5,434,903 to 12,591,136 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Hamill John P.
30 Jan 2026
SrVP/CFO/Prin Fin & Acct Ofcr
Buy
5,700
$0.89
$5.07K
Gilad Oren
30 Jan 2026
President/CEO
Buy
28,100
$0.89
$25.01K
Hamill John P.
10 Dec 2025
SrVP/CFO/Prin Fin & Acct Ofcr
Buy
5,000
$1.17
$5.83K
Duey Marc
10 Dec 2025
Director
Buy
21,459
$1.17
$25.00K

What was left out

Form 4 filings counted 17
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 55,350
History held since 7 Oct 2019